Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A viral infectious disease that results in increased proliferation of affected CD4 lymphocytes, has material basis in Human T-lymphotropic virus 1, which is transmitted by sexual contact, transmitted by contaminated needles used by intravenous-drug users, and transmitted by breast feeding. The person infected with HTLV-1 eventually develop an often rapidly fatal leukemia, while others will develop a debilitative myelopathy, uveitis, infectious dermatitis, or another inflammatory disorder.
Biomarker and diagnostic research for human T-lymphotropic virus 1 infectious disease has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
213 publications have been identified in PubMed for human T-lymphotropic virus 1 infectious disease. Kisho has analyzed 126 by research type. Research spans Review / Meta-Analysis (40%), Basic Science / Preclinical (29%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 51 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:13 PM UTC
40%
Laboratory research | 36 | 29% |
Disease patterns and progression | 19 | 15% |
Testing and diagnosis research | 8 | 6% |
Patient case studies | 6 | 5% |
New treatment approaches | 3 | 2% |
Other research | 2 | 2% |
Clinical study results | 1 | 1% |
Cilento NE (2026). [PMID: 41822515](https://pubmed.ncbi.nlm.nih.gov/41822515/). *Front Immunol*. [Epidemiology / Natural History]
Brebant D (2026). [PMID: 41391835](https://pubmed.ncbi.nlm.nih.gov/41391835/). *J Gynecol Obstet Hum Reprod*. [Diagnostic / Biomarker]
Grimley SL (2026). [PMID: 42043191](https://pubmed.ncbi.nlm.nih.gov/42043191/). *Viruses*. [Epidemiology / Natural History]
Konan B (2026). [PMID: 41891492](https://pubmed.ncbi.nlm.nih.gov/41891492/). *J Med Virol*. [Epidemiology / Natural History]
Shichijo T (2026). [PMID: 41498998](https://pubmed.ncbi.nlm.nih.gov/41498998/). *Int J Hematol*. [Review / Meta-Analysis]
Garrido-Pinzás G (2026). [PMID: 41729993](https://pubmed.ncbi.nlm.nih.gov/41729993/). *PLoS Negl Trop Dis*. [Case Report / Case Series]
Letafati A (2026). [PMID: 41714539](https://pubmed.ncbi.nlm.nih.gov/41714539/). *J Neurovirol*. [Review / Meta-Analysis]
Yamaguchi S (2026). [PMID: 41855158](https://pubmed.ncbi.nlm.nih.gov/41855158/). *PLoS Negl Trop Dis*. [Case Report / Case Series]
Yang M (2026). [PMID: 42025747](https://pubmed.ncbi.nlm.nih.gov/42025747/). *Int J Infect Dis*. [Epidemiology / Natural History]
Alava-Flores WG (2026). [PMID: 41902246](https://pubmed.ncbi.nlm.nih.gov/41902246/). *Viruses*. [Epidemiology / Natural History]